Last updated: August 23, 2026
Trudhesa, Impel Pharmaceuticals’ precision olfactory delivery product for acute migraine, has moved from a venture-backed launch asset to a commercial product owned by Assertio Holdings. Its market position depends on differentiated nasal delivery, reimbursement access, migraine-treatment switching behavior, and the ability to expand prescriptions beyond patients who cannot use oral or conventional nasal therapies. Financial performance has improved from the early launch period, but the product remains exposed to limited brand awareness, payer controls, and competition from established triptans, gepants, and injectable CGRP therapies.
What is Trudhesa and how does it work?
Trudhesa is a prescription nasal spray containing dihydroergotamine mesylate, or DHE, for the acute treatment of migraine with or without aura in adults. The FDA approved Trudhesa on September 2, 2021, under NDA 214560.[1]
Trudhesa uses Impel’s Precision Olfactory Delivery, or POD, technology. The device is designed to deliver medication into the upper nasal cavity, including the olfactory region. The delivery approach seeks to reduce swallowing and gastrointestinal absorption and to provide more consistent systemic exposure than conventional nasal sprays.
| Attribute |
Trudhesa |
| Active ingredient |
Dihydroergotamine mesylate |
| Dosage form |
Nasal spray |
| Indication |
Acute treatment of migraine with or without aura |
| FDA approval |
September 2, 2021 |
| Original developer |
Impel Pharmaceuticals |
| Current commercial owner |
Assertio Holdings |
| Regulatory pathway |
New drug application |
| Drug class |
Ergot alkaloid |
| Biosimilar status |
Not applicable |
| Principal differentiation |
Upper-nasal delivery through POD technology |
The product is not intended for migraine prevention. It is contraindicated in patients with certain cardiovascular conditions and in patients using potent CYP3A4 inhibitors because of the risk of ergot toxicity.[2]
What is the financial trajectory for Trudhesa?
Trudhesa generated limited revenue during its initial launch under Impel, followed by a commercial transition after Impel entered bankruptcy proceedings. Assertio acquired substantially all of Impel’s operating assets and assumed commercial responsibility for Trudhesa in late 2023 and early 2024.[3]
Public-company reporting indicates that Trudhesa has become a material growth product within Assertio’s portfolio. The product’s revenue trajectory has been supported by:
- A larger specialty-pharmacy and prescriber network.
- Increased use among patients with inadequate response to oral acute therapies.
- Improved commercial execution after the transfer from Impel to Assertio.
- Cross-selling through Assertio’s existing commercial infrastructure.
- Continued interest in non-oral acute migraine delivery.
The early launch period was constrained by the COVID-era operating environment, limited field infrastructure, patient access friction and the commercial resources required to educate neurologists and headache specialists. Assertio’s acquisition provided a more established specialty-pharmaceutical platform.
| Period |
Commercial status |
Financial interpretation |
| 2021 |
FDA approval and launch preparation |
Initial revenue base; high launch spending |
| 2022 |
Early commercial launch under Impel |
Product adoption remained below the scale required to support Impel independently |
| 2023 |
Impel financial distress and asset-sale process |
Commercial disruption and ownership uncertainty |
| 2024 |
Assertio-led commercialization |
Increased strategic focus and broader operating support |
| 2025 onward |
Portfolio integration and prescription expansion |
Growth depends on payer access, refill persistence and migraine-market differentiation |
Assertio does not report Trudhesa as a separately traded public company. Its financial contribution must therefore be assessed through Assertio’s annual and quarterly filings, product commentary and portfolio-level results.[3]
The key financial question is whether Trudhesa can develop into a durable specialty product rather than remain a niche rescue therapy. The product has a higher potential value per treated patient than many low-cost generic migraine therapies, but it also requires prescriber education and payer management.
How does Trudhesa compare with competing migraine drugs?
Trudhesa competes across several segments rather than against one direct substitute.
| Competitor category |
Representative products |
Competitive effect on Trudhesa |
| Generic triptans |
Sumatriptan, rizatriptan, eletriptan |
Low-cost first-line alternatives |
| Conventional DHE nasal spray |
Migranal and authorized generic equivalents |
Same active ingredient, less differentiated delivery |
| Oral gepants |
Ubrelvy, Nurtec ODT, Zavzpret |
Strong competition from non-ergot acute therapies |
| Injectable CGRP products |
Various branded therapies |
Compete for patients requiring rapid or reliable treatment |
| Traditional injectable DHE |
Generic injectable DHE |
Used in emergency or specialty settings |
| Nonprescription analgesics |
NSAIDs and combination products |
Compete in mild-to-moderate migraine |
Trudhesa’s commercial proposition is strongest in patients who experience nausea, vomiting, gastroparesis, poor oral absorption, inadequate triptan response or a need for a non-oral option. Gepants are a major competitive risk because they avoid vasoconstriction and have broader use among patients for whom ergot products are unsuitable.
Trudhesa has a potential advantage over conventional nasal DHE products because its delivery system is part of the product’s clinical and commercial differentiation. Its limitation is that the active ingredient, DHE, is an established molecule with well-known cardiovascular restrictions.
What patents protect Trudhesa?
Trudhesa’s intellectual-property position is based primarily on drug-delivery technology, device configuration, formulation and use of the product rather than on new-molecule protection for DHE.
The relevant protection categories include:
- Precision Olfactory Delivery technology.
- Nasal-device architecture.
- Methods for delivering DHE to the upper nasal cavity.
- Formulation and dose-delivery parameters.
- Method-of-use claims directed to acute migraine treatment.
The FDA Orange Book is the controlling source for patents submitted by the NDA holder for listed drug products. Orange Book listings can change through patent submissions, corrections, delistings and regulatory updates.[4] Trudhesa’s patent estate should therefore be evaluated against the current Orange Book record and the underlying USPTO prosecution histories rather than against marketing materials alone.
The principal commercial patent risk is unlikely to be early loss of all protection. The more relevant question is whether a generic entrant can design around device or delivery claims while relying on the established DHE active ingredient.
When does Trudhesa lose exclusivity?
Trudhesa did not receive conventional five-year new chemical entity exclusivity because dihydroergotamine was previously approved. The product could receive regulatory exclusivity associated with new clinical investigations and the new dosage form, but this period is shorter than new-molecule exclusivity.
The FDA approval date was September 2, 2021. Any three-year clinical-investigation exclusivity associated with approval would generally have expired in September 2024, subject to the precise scope of the listed exclusivity and the FDA’s regulatory records.[1]
Patent protection is likely to remain the principal barrier to generic entry after regulatory exclusivity ends. Device and delivery patents can extend commercial protection well beyond the initial approval period, although their enforceability depends on claim scope, prosecution history, validity and the design of an abbreviated new drug application.
Geographic coverage
U.S. protection is the most commercially important because the U.S. is the principal market for Trudhesa. International coverage is less significant because the product’s commercial infrastructure and FDA approval are concentrated in the United States. The value of foreign patents depends on national filings, granted claims, maintenance payments and local migraine-market economics.
What is the Orange Book status of Trudhesa?
Trudhesa is an FDA-approved prescription drug listed under NDA 214560. Its Orange Book status should be reviewed for:
- Listed patents and patent-use codes.
- Pediatric-exclusivity adjustments.
- Patent expiration dates.
- Whether each patent covers the drug, device, formulation or method of use.
- Any approved generic applications with Paragraph IV certifications.
The Orange Book does not by itself establish that every listed patent will withstand validity or infringement challenges. It identifies patents submitted by the NDA holder and provides the statutory framework for generic certification and possible litigation.[4]
Which companies are challenging Trudhesa patents?
No widely reported, commercially significant Paragraph IV litigation against Trudhesa has established a generic launch date. The absence of public litigation is commercially relevant, but it does not eliminate future challenge risk.
A generic applicant could pursue one of four routes:
- Certify that no relevant patent is listed.
- Certify that a listed patent has expired.
- File a Paragraph III certification with a delayed launch.
- File a Paragraph IV certification alleging invalidity, unenforceability or non-infringement.
A challenge would likely focus on whether the applicant’s device falls within claims covering the POD delivery system or whether the relevant claims are invalid for obviousness, lack of written description or inadequate enablement.
What generic entry risks exist for Trudhesa?
Generic entry risk is moderate over the medium term and higher over the long term.
The main barriers are:
- Device complexity compared with a conventional tablet.
- Potential drug-device combination-product requirements.
- Need to demonstrate pharmaceutical equivalence and bioequivalence.
- Difficulty designing a substitute device without infringing delivery claims.
- Limited commercial attractiveness if the market remains concentrated in a narrow specialist population.
The principal vulnerabilities are:
- DHE is an old active ingredient.
- The product does not have new-molecule exclusivity.
- Generic manufacturers can use established regulatory and manufacturing knowledge for DHE.
- Gepants may reduce the market available to future DHE products.
- Payers may prefer lower-cost alternatives.
A generic could launch through an authorized-generic arrangement, an approved alternative device or a settlement that provides a launch date before the latest patent expiration. No publicly established settlement agreement has created a known generic entry date.
How strong is the Trudhesa patent estate?
The estate is stronger as a delivery-platform estate than as a molecule estate.
| Patent-estate dimension |
Assessment |
| Active ingredient |
Weak exclusivity because DHE is established |
| Device technology |
Potentially meaningful if claims are narrow and difficult to design around |
| Formulation |
Moderate, depending on claim breadth and prior art |
| Method of use |
Moderate to weak if claims overlap standard acute-migraine treatment |
| Regulatory exclusivity |
Limited relative to a new chemical entity |
| Manufacturing know-how |
Potentially important but not fully visible through public patent records |
| Litigation deterrence |
Dependent on Orange Book listings and commercial value of the market |
Manufacturing know-how may include nozzle design, dose metering, plume characteristics, fill volume, stability, container-closure compatibility and upper-nasal deposition. These elements can create practical barriers even where patent claims are vulnerable. Trade secrets and process controls are not fully captured in public patent databases.
What FDA regulatory issues affect Trudhesa?
The FDA approved Trudhesa for acute migraine treatment, not prevention or general headache treatment.[1] Regulatory growth opportunities must remain within the approved labeling unless Assertio obtains supplemental approval.
Potential regulatory and commercial constraints include:
- Cardiovascular contraindications associated with DHE.
- Drug-drug interaction restrictions.
- Patient and prescriber familiarity with newer CGRP therapies.
- The need to maintain device reliability and dose consistency.
- Combination-product manufacturing controls.
- Postmarketing pharmacovigilance for ergot-related adverse events.
The FDA approval gives Trudhesa a defined regulatory position, but it does not remove the clinical limitations of the DHE class.
What licensing deals and ownership changes affect Trudhesa?
Impel developed Trudhesa through its proprietary POD platform. Assertio later acquired Impel’s commercial assets during Impel’s financial restructuring and assumed control of the product’s commercialization.[3]
The transaction changed Trudhesa’s economics in three ways:
- Commercial spending became part of a broader specialty-pharmaceutical portfolio.
- Assertio gained the ability to use existing distribution and market-access capabilities.
- Impel’s standalone financing requirements were removed from the product’s operating structure.
The transaction also creates integration risk. Assertio must allocate sales, medical-affairs and market-access resources across Trudhesa and its other products. A product with attractive prescription growth may still have limited incremental profitability if commercialization costs remain high.
What is the revenue exposure for Assertio?
Trudhesa is strategically important because it adds growth potential to a portfolio that includes mature or established specialty products. Its contribution is smaller than the company’s total revenue base, but it can have an outsized effect on growth rates if prescriptions expand from a low starting point.
The main financial variables are:
- Net price after payer rebates and patient support.
- New-patient starts.
- Repeat-fill rates.
- Commercial-insurance coverage.
- Specialty-pharmacy abandonment.
- Gross-to-net deductions.
- Sales-force and promotional costs.
- Manufacturing cost per device.
- The timing of generic or competing branded entry.
Trudhesa’s financial trajectory is therefore more sensitive to prescription growth and access improvements than to price increases. Large price increases could accelerate payer restrictions and encourage substitution.
What launch scenarios should investors and competitors monitor?
Upside scenario
Trudhesa gains adoption among patients who cannot tolerate oral treatment or do not respond to triptans. Assertio improves coverage, increases refill persistence and uses its commercial platform to lower customer-acquisition costs.
Base scenario
The product remains a profitable niche therapy with steady growth among headache specialists. Gepants and generic triptans limit broad primary-care adoption, but patent protection prevents immediate generic erosion.
Downside scenario
Payers place Trudhesa behind gepants or generic triptans, prescriptions remain concentrated among specialists and a generic applicant challenges the delivery patents. Revenue growth slows before the product reaches scale.
Key Takeaways
- Trudhesa is an FDA-approved acute migraine nasal spray based on DHE and Impel’s POD delivery technology.
- Assertio became the commercial owner after acquiring Impel’s assets during Impel’s bankruptcy-related restructuring.
- The product’s financial trajectory improved after the ownership transition, but it remains a niche specialty-migraine product.
- Its strongest commercial target is the patient who needs a non-oral therapy or has failed conventional acute treatments.
- Generic risk is moderated by device and delivery patents but increased by the age of the DHE molecule and the expiration of short-term regulatory exclusivity.
- Gepants are the most important branded competitive threat because they avoid the vasoconstrictive limitations of DHE.
- No publicly established Paragraph IV settlement or generic launch date has materially changed Trudhesa’s market outlook.
- Patent strength depends on the breadth and enforceability of the delivery-system claims, not on the DHE molecule itself.
FAQs
Is Trudhesa a CGRP migraine drug?
No. Trudhesa contains dihydroergotamine mesylate, an ergot alkaloid. It is not a CGRP receptor antagonist or CGRP monoclonal antibody.
Can Trudhesa be used for migraine prevention?
No. The FDA-approved indication covers acute treatment of migraine with or without aura in adults. It is not approved for preventive treatment.[1]
Is there a generic version of Trudhesa?
No publicly established generic launch has displaced Trudhesa. Future generic competition would likely involve an abbreviated new drug application and possible device, formulation or patent litigation.
Does Trudhesa have biosimilar risk?
No. Biosimilars apply to biological products. Trudhesa is a small-molecule drug-device combination product, so the relevant competitive pathway is generic drug approval rather than biosimilar approval.
Why might a physician choose Trudhesa over oral migraine medicine?
Trudhesa may be considered when a patient has nausea, vomiting, impaired gastric absorption, poor response to oral medicines or a need for a non-oral acute treatment. Its DHE-related cardiovascular restrictions limit use in certain patients.
References
-
U.S. Food and Drug Administration. (2021). Trudhesa prescribing information. FDA.
-
U.S. Food and Drug Administration. (2021). Drugs@FDA: Trudhesa, NDA 214560. FDA.
-
Assertio Holdings, Inc. (2024). Annual report on Form 10-K. U.S. Securities and Exchange Commission.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.
